Impact of blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers.
Optimization of hemodialysis treatment parameters and the characteristics of the dialyzer are crucial for short- and long-term outcome of end stage renal disease patients. The new high-flux membrane Helixone in the dialyzer of the FX series (Fresenius Medical Care, Germany) has interesting features, such as the relationship of membrane thickness and capillary diameter which increases middle molecule elimination by convection, as well as higher capillary packing and microondulation to improve the dialysate flow and distribution. Blood flow, dialysate flow and surface area are the main determinants of the performance of a dialyzer, however the impact of each parameter on small and middle molecule clearance in high flux dialysis has not been well explored. In order to find the best treatment condition for the new dialyzer series, we evaluated urea, creatinine, phosphate clearances and reduction rate of beta2-microglobulin in ten stable patients treated with different blood flows (effective Qb 280 and 360 ml/min), dialysate flow (Qd 300 or 500 ml/min) and dialyzer surfaces (1.4 and 2.2 m2, FX60 or FX100). KoA and Kt/V were also calculated. Blood flow, dialysate flow and surface area demonstrated a significant and independent effect on clearance of urea, creatinine and phosphate, as well as on Kt/V. Small solute clearance was stable over the treatment. In contrast to small solutes, reduction rate of beta2-microglobulin was related to increasing dialyzer surface only. The new dialyzer design of the FX series proves highly effective due to improved dialysate distribution and reduced diffusive resistance as shown by the small solute clearance. A high reduction rate of beta2-microglobulin is favored by improved fiber geometry and pore size distribution. These findings have potential long-term benefits for the patient.
Mandolfo
S
S
Renal Unit, Ospedale Maggiore, Lodi, Italy. nefrodialisi.lodi@ao.lodi.it
Malberti
F
F
Imbasciati
E
E
Cogliati
P
P
Gauly
A
A
D000368:Aged; D001672:Biocompatible Materials / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D015314:Dialysis Solutions / Q000493:pharmacokinetics*; D004058:Diffusion; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008567:Membranes, Artificial; D008875:Middle Aged; D010316:Particle Size; D011108:Polymers / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000295:instrumentation*; D013450:Sulfones / Q000627:therapeutic use*; D001613:beta 2-Microglobulin / Q000493:pharmacokinetics
D001672:Biocompatible Materials; D015314:Dialysis Solutions; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; D001613:beta 2-Microglobulin; C017662:polysulfone P 1700